• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Autolus Therapeutics plc (AUTL)

American Depository Receipt
Sell: $1.53|Buy: $1.56|Change: 0.03 (2.00%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Find out more

This share can be held in a Dealing accountSIPP

Company profile

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3,AUTO5, AUTO6, AUTO7 & AUTO8.

Address

58 Wood Lane
Forest House, White City
London
GBR
W12 7RZ

Telephone

+44 2038296230

Website

https://www.autolus.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Autolus Therapeutics PLC Second Quarter Earnings Conference Call for 20262026-08-12T08:30:00
Autolus Therapeutics PLC Second Quarter Earnings Results for 20262026-08-12T00:00:00
Autolus Therapeutics PLC Annual General Meeting for 20262026-06-26T10:00:00
Autolus Therapeutics PLC First Quarter Earnings Conference Call for 20262026-05-08T08:30:00
Autolus Therapeutics PLC First Quarter Earnings Results for 20262026-05-08T00:00:00
Autolus Therapeutics PLC Fourth Quarter Earnings Conference Call for 20252026-03-20T08:30:00
Autolus Therapeutics PLC Fourth Quarter Earnings Results for 20252026-03-20T00:00:00
Autolus Therapeutics PLC Annual Report for 20252026-03-20T00:00:00
Autolus Therapeutics PLC Third Quarter Earnings Conference Call for 20252025-11-12T08:30:00
Autolus Therapeutics PLC Third Quarter Earnings Results for 20252025-11-12T00:00:00

Previous key dates

NameKey Date
Autolus Therapeutics PLC Second Quarter Earnings Conference Call for 20252025-08-12T08:30:00
Autolus Therapeutics PLC Second Quarter Earnings Result for 20252025-08-12T00:00:00
Autolus Therapeutics PLC Annual General Meeting for 20252025-06-26T10:00:00
Goldman Sachs 46th Annual Global Healthcare Conference2025-06-11T13:20:00
Jefferies Global Healthcare Conference2025-06-05T15:10:00
Autolus Therapeutics PLC First Quarter Earnings Conference Call for 20252025-05-08T08:30:00
Autolus Therapeutics PLC First Quarter Earnings Results for 20252025-05-08T00:00:00
Autolus Therapeutics to Host R&D Investor Event2025-04-23T08:30:00
24th Annual Needham Virtual Healthcare Conference2025-04-09T09:30:00
Autolus Therapeutics PLC Fourth Quarter Earnings Conference Call for 20242025-03-20T08:30:00
Autolus Therapeutics PLC Fourth Quarter Earnings Result for 20242025-03-20T00:00:00
Autolus Therapeutics PLC Annual Report for 20242025-03-20T00:00:00
Leerink Global Biopharma Conference 20252025-03-12T08:40:00
Autolus Therapeutics PLC Third Quarter Earnings Conference Call for 20242024-11-12T08:30:00
Autolus Therapeutics PLC Third Quarter Earnings Results for 20242024-11-12T00:00:00
Analyst/Investor Event to Discuss the FDA Approval of AUCATZYL®2024-11-11T08:30:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.